Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naive first episode psychosis patients aged 15 to 25 years.

Next Previous
X
Search
Trial Profile

A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naive first episode psychosis patients aged 15 to 25 years.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Psychotic disorders
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 26 Jan 2011 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 18 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top